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Discussion
In 2010, 571 cases with NHL or BC were hospitalized
due to FN. Average cost per FN hospitalization are
considerable but lie within possible SwissDRG
reimbursement rates. Main limitations of this study are
the indirect identification of FN cases by ICD-10
diagnoses and the small sample in the cost analysis.
Our results suggest that FN leads to considerable risk
of death and incurs high in-hospital care cost in
Switzerland.
women men
Proportion of all hospitalizations
Aggressive NHL 70/750 (9.3%) 92/829 (11.1%)
Indolent NHL 10/296 (3.4%) 19/313 (6.1%)
Rest of NHL 44/1'020 (4.3%) 79/1'183 (6.7%)
Breast cancer 255/9'650 (2.6%) 2/89 (2.2%)
Average length of hospital stay (days)
Aggressive NHL 19.2 17.3
Indolent NHL 11.8 11.4
Rest of NHL 15.3 15.2
Breast cancer 8.8 10.5
Mortality among hospitalizations
Aggressive NHL 3/70 (4.3%) 8/92 (8.7%)
Indolent NHL 0/10 (0%) 0/19 (0.0%)
Rest of NHL 4/44 (9.1%) 10/79 (12.7%)
Breast cancer 11/255 (4.3%) 0/2 (0%)
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Objectives
Febrile neutropenia (FN) can be a serious complication
of chemotherapy (CHT), increasing mortality risk and
healthcare costs [1, 2]. Incidence and inpatient hospital
costs of FN in Switzerland are currently not reported.
The study aimed to: 1. Estimate the number of CHT
induced FN-related hospitalizations. 2. Assess inpatient
hospital costs per FN event in Switzerland.
Results
1’202 NHL patients and 6’391 female BC patients were
hospitalized in 2010 for the first time. Corresponding
annual incidence data from NICER were 1’468 NHL
patients and 5’388 female BC patients. Differences can
be explained by the fact that MedStat only includes
inpatient stays and does not allow for identification of
recurrent tumors.
7.2% of all hospitalizations in NHL-patients and 2.6% of
all hospitalizations in BC-patients were related to FN
(table 1). Average length of stay was 16.4 days for NHL
and 8.8 days for BC (table 1). The in-hospital mortality
was 8.0% for NHL and 4.3% for BC (table 1).
Cost data was available from 18 patients with basic
insurance (6 with BC and 12 with NHL). Average costs
per stay were CHF 14’006 in NHL and CHF 10’020 in
BC patients (table 2). Cost composition in KSW (figure
1) reflects standard of care in Switzerland: Nursing
forms the largest cost share followed by diagnostic
imaging (thorax x-ray) and lab tests (urinalysis, blood
count and blood cultures).
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Methods
The main data source was MedStat, a comprehensive
database of all Swiss hospitalizations from 1997-2010
[3]. We focused on breast cancer (BC) and Non-
Hodgkin lymphoma (NHL). These two types of cancer
are often treated with myelosuppressive CHT.
BC and NHL cases were identified from ICD-10-GM
codes. Hospitalizations for FN were identified by a
simultaneous code of BC or NHL and neutropenia [4].
Incident cases of cancer were identified as patients
treated in 2010 for the first time since 2002. Results
were compared with data from the Foundation National
Institute for Cancer Epidemiology and Registration
(NICER) [5]. Cost data were derived from the cantonal
hospital of Winterthur (KSW). Four clinical experts in the
inpatient treatment of FN who represent university and
cantonal hospitals as well as the German- and French-
speaking part of Switzerland were interviewed to
understand BC, NHL and FN treatment practice.
Table 1: Number of FN-related hospitalizations, length of 
stay and mortality
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Table 2: Inpatient hospital costs per FN event [CHF]
Figure 1: Cost composition (N=18)
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Source: Swiss Medical Statistics of Hospitals (FSO, 2011)
Source: Cantonal hospital of Winterthur
total cost cost per day length of stay [days]
Non-Hodgkin lymphoma (N=12)
average 14'006 983 14.3
median 8'399 843 10
Breast cancer (N=6)
average 10'020 1'822 5.5
median 4'208 934 4.5
